- Home
- ONVO vs PPBT Comparison
ONVO vs PPBT Comparison
Compare ONVO & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONVO
- PPBT
- Stock Information
- Founded
- ONVO 2007
- PPBT 2010
- Country
- ONVO United States
- PPBT Israel
- Employees
- ONVO N/A
- PPBT N/A
- Industry
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- ONVO Health Care
- PPBT Health Care
- Exchange
- ONVO Nasdaq
- PPBT Nasdaq
- Market Cap
- ONVO 5.6M
- PPBT 8.8M
- IPO Year
- ONVO N/A
- PPBT N/A
- Fundamental
- Price
- ONVO $0.45
- PPBT $4.51
- Analyst Decision
- ONVO
- PPBT Strong Buy
- Analyst Count
- ONVO 0
- PPBT 2
- Target Price
- ONVO N/A
- PPBT $126.50
- AVG Volume (30 Days)
- ONVO 214.6K
- PPBT 212.9K
- Earning Date
- ONVO 02-06-2025
- PPBT 11-15-2024
- Dividend Yield
- ONVO N/A
- PPBT N/A
- EPS Growth
- ONVO N/A
- PPBT N/A
- EPS
- ONVO N/A
- PPBT N/A
- Revenue
- ONVO $103,000.00
- PPBT N/A
- Revenue This Year
- ONVO $59.08
- PPBT N/A
- Revenue Next Year
- ONVO $18.24
- PPBT N/A
- P/E Ratio
- ONVO N/A
- PPBT N/A
- Revenue Growth
- ONVO N/A
- PPBT N/A
- 52 Week Low
- ONVO $0.32
- PPBT $2.00
- 52 Week High
- ONVO $1.74
- PPBT $20.60
- Technical
- Relative Strength Index (RSI)
- ONVO 59.27
- PPBT 55.33
- Support Level
- ONVO $0.42
- PPBT $3.18
- Resistance Level
- ONVO $0.52
- PPBT $5.20
- Average True Range (ATR)
- ONVO 0.05
- PPBT 0.53
- MACD
- ONVO 0.01
- PPBT 0.07
- Stochastic Oscillator
- ONVO 65.53
- PPBT 65.84
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.